Joaquim Bellmunt
Beth Israel Deaconess Medical Center
725 Papers
5.2K Citations
Joaquim Bellmunt is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Medicine & Bladder cancer. The author has an hindex of 82, co-authored 660 publications. Previous affiliations of Joaquim Bellmunt include University of Cambridge & Brigham and Women's Hospital.
Chat about Author
Papers
New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.
Gregory R. Pond,Guenter Niegisch,Jonathan E. Rosenberg,Robert Dreicer,Thomas Powles,Andrea Necchi,Xiao X. Wei,Petros Grivas,Arjun Vasant Balar,Matthew D. Galsky,Sandy Srinivas,Toni K. Choueiri,Joaquim Bellmunt,Dean F. Bajorin,Guru Sonpavde +14 more
TL;DR: The association of prognostic factors recognized in the chemotherapy setting, liver metastasis, anemia, treatment-free interval, albumin, neutrophil-lymphocyte ratio, eosinophil count, platelet count, and immune cell PD-L1 status by IHC with OS was evaluated.
11
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Joaquim Bellmunt,Pablo Maroto-Rey,Jose Manuel Trigo,Joan Carles,Vicente Guillem,Jose A. Lopez-Martin,Antonio Antón-Torres,Leyrer Urruticoechea +7 more
TL;DR: In patients with mRCC who were unwilling to receive or intolerant to immunotherapy, treatment with sorafenib led to a high rate of disease control with toxicities that were generally mild and manageable.
11
First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.
Joaquim Bellmunt,Bernhard J. Eigl,Elżbieta Senkus-Konefka,Yohann Loriot,Przemyslaw Twardowski,Daniel Castellano,Normand Blais,Srikala S. Sridhar,Cora N. Sternberg,Margitta Retz,Brent A. Blumenstein,Cindy Jacobs,Patricia S. Stewart,Daniel P. Petrylak +13 more
TL;DR: Apatorsen (A; OGX-427), a novel antisense oligonucleotide, inhibits Hsp27 production and can potentially enhance the efficacy of chemotherapy and evaluate efficacy and safety of A in combination with gemcitabine and cisplatin in patients with advanced BC.
10
Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.
Ashish M. Kamat,Seth P. Lerner,Peter McL. Black,Joaquim Bellmunt,Colin P.N. Dinney,Noah M. Hahn,Michael A. O’Donnell,Diane Zipursky Quale +7 more
- 27 Jul 2017
TL;DR: This research presents a novel, scalable, scalable and scalable approach that aims to provide real-time information about the BRCA1/BRCA2 “spatially aggregating immune checkpoints” and their role in disease progression.
Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome
Laura Segalés,Nuria Juanpere,Marta Lorenzo,Raquel Albero-González,Lluís Fumadó,Lluís Cecchini,Joaquim Bellmunt,Josep Lloreta-Trull,Silvia Hernández-Llodrà +8 more
TL;DR: Investigating ETV1, ETV4, and ETV5 overexpression, with or without PTEN loss, and their association with grade group (GG), pathological stage, focality, and PSA recurrence in PrCa concluded that non-ERG ETS overeexpression has a non-negligible role in Pr Ca.
10